A Study to Evaluate the Efficacy of Lastacaft® Compared to Pataday™ and Placebo in Patients With Acute Allergic Conjunctivitis
NCT ID: NCT01732757
Last Updated: 2014-01-14
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
157 participants
INTERVENTIONAL
2012-11-30
2012-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study to Evaluate the Duration of LASTACAFT® in Acute Allergic Conjunctivitis
NCT01470118
Study of DE-114 Ophthalmic Solution in Patients With Allergic Conjunctivitis
NCT01363700
A Single-Center Evaluation of the Anti-Inflammatory Effects of Lastacaft as Measured by In-Vivo Confocal Microscopy
NCT02308501
Evaluation of Efficacy of Ophthalmic Solution in Induced Acute Allergic Conjunctivitis
NCT00241319
A Study of Patient Perception and Quality of Life Associated With the Use of Olopatadine 0.2% in Subjects With Allergic Conjunctivitis
NCT01272089
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Lastacaft®
One drop of Lastacaft® (Alcaftadine 0.25%) administered in both eyes on Day 0.
Alcaftadine 0.25%
One drop of Lastacaft® (Alcaftadine 0.25%) administered in both eyes on Day 0.
Pataday™
One drop of Pataday™ (Olopatadine 0.2%) administered in both eyes on Day 0.
Olopatadine 0.2%
One drop of Pataday™ (Olopatadine 0.2%) administered in both eyes on Day 0.
Placebo (dextran 70 0.1%/hydroxypropyl methylcellulose 0.3%)
One drop of Placebo (dextran 70 0.1%/hydroxypropyl methylcellulose 0.3%) administered in both eyes on Day 0.
dextran 70 0.1%/hydroxypropyl methylcellulose 0.3%
One drop of placebo (dextran 70 0.1%/hydroxypropyl methylcellulose 0.3%) administered in both eyes on Day 0.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Alcaftadine 0.25%
One drop of Lastacaft® (Alcaftadine 0.25%) administered in both eyes on Day 0.
Olopatadine 0.2%
One drop of Pataday™ (Olopatadine 0.2%) administered in both eyes on Day 0.
dextran 70 0.1%/hydroxypropyl methylcellulose 0.3%
One drop of placebo (dextran 70 0.1%/hydroxypropyl methylcellulose 0.3%) administered in both eyes on Day 0.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Able to avoid wearing contact lenses for at least 72 hours prior to and during the study trial period.
Exclusion Criteria
* Ocular surgery within 3 months prior to the first visit or refractive surgery within the past 6 months.
* Have any planned surgery during the study or 30 days after the study.
10 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Allergan
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Medical Director
Role: STUDY_DIRECTOR
Allergan
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Memphis, Tennessee, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
McLaurin EB, Marsico NP, Ackerman SL, Ciolino JB, Williams JM, Villanueva L, Hollander DA. Ocular itch relief with alcaftadine 0.25% versus olopatadine 0.2% in allergic conjunctivitis: pooled analysis of two multicenter randomized clinical trials. Adv Ther. 2014 Oct;31(10):1059-71. doi: 10.1007/s12325-014-0155-3. Epub 2014 Sep 27.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
GMA-LAS-12-023
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.